Výsledky vyhledávání - "E, Rodríguez Braun"

Colorectal serrated adenocarcinoma shows a different profile of oncogene mutations, MSI status and DNA repair protein expression compared to conventional and sporadic MSI-H carcinomas

Autor: J. García-Solano, P. Conesa-Zamora, P. Carbonell, J. Trujillo-Santos, D. Torres-Moreno D, I. Pagán-Gómez, E. Rodríguez-Braun, M. Pérez-Guillermo

Publikováno v: International Journal of Cancer. 131:1790-1799

Molecular characterization has been extensively studied in serrated polyps but very little is known in serrated adenocarcinomas (SACs). We analyzed the incidence of KRAS, BRAF and PIK3CA mutations, microsatellite instability (MSI) status and loss of

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3f247a7adc43a2c396e5c841e8028ab5
https://doi.org/10.1002/ijc.27454

Zobrazit plný text záznamu

Phase I Study of the Selective Aurora A Kinase Inhibitor MLN8054 in Patients with Advanced Solid Tumors: Safety, Pharmacokinetics, and Pharmacodynamics

Autor: Elena Elez, Teresa Macarulla, Yih Lee, José Baselga, Hua Liu, Josep Tabernero, E. Rodríguez-Braun, Gemma Sala, Omar Eton, Vaishali Shinde, Hadi Danaee, Arijit Chakravarty, Susana Roselló, Jeffrey Ecsedy, Andrés Cervantes, Inma Blasco, Howard Fingert, Douglas Bowman

Publikováno v: Molecular Cancer Therapeutics. 9:2844-2852

This phase I trial examined the safety, pharmacokinetics, and pharmacodynamics of MLN8054, an oral, selective, small-molecule inhibitor of Aurora A kinase. Patients with advanced solid tumors received increasing doses of MLN8054 in 28-day cycles unti

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd5518474361aca8a0606cb199cf231a
https://doi.org/10.1158/1535-7163.mct-10-0299

Zobrazit plný text záznamu

Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study

Autor: Maria Eugenia Vega-Villegas, Fernando Rivera, Fortunato Ciardiello, Andrés Cervantes, Francisco Javier Ramos, E. Rodríguez-Braun, José Baselga, Teresa Macarulla, Susana Roselló, Erika Martinelli, S. Liebscher, Josep Tabernero, O. Kisker

Publikováno v: Annals of Oncology. 21:1537-1545

Background This phase I dose-escalation study was designed to determine the maximum tolerated dose (MTD) and recommended dose of cetuximab administered on an every-second-week schedule to patients with metastatic colorectal cancer, on the basis of sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::457ca5cdec6a4250633dcea4bb85f86e
https://doi.org/10.1093/annonc/mdp549

Zobrazit plný text záznamu

Akademický článek

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Aurora kinase inhibitors: a new class of drugs targeting the regulatory mitotic system

Autor: E. Rodríguez-Braun, Andrés Cervantes, Desamparados Roda, José Alejandro Pérez Fidalgo, Susana Roselló

Publikováno v: ResearcherID

The present review gives a perspective on the Aurora kinase family members, their function in normal cells, their role in cancer progression as well as their potential as target for anticancer treatment. Mitosis has been an important target for antic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::948ccb0070214804d4e03ce052a53f6b
https://doi.org/10.1007/s12094-009-0447-2

Zobrazit plný text záznamu

Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial

Autor: Paloma Martín-Martorell, Ana Bosch, Andrés Cervantes, E. Rodríguez-Braun, Susana Roselló, Isabel Chirivella

Publikováno v: British Journal of Cancer

This is a phase II institutional exploratory trial of biweekly irinotecan and cetuximab administration regimen in metastatic colorectal cancer patients progressing to at least one previous chemotherapy line. A total of 40 patients were treated betwee

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a00e5145d615b15874d9626fab09d8f
https://doi.org/10.1038/sj.bjc.6604530

Zobrazit plný text záznamu

Flegmasia cerulea dolens en paciente con carcinoma testicular

Autor: A.I. Teruel Casasus, A. Insa Mollá, I. Chirivella Gonzalez, A. Cervantes Ruiperez, A. Magro Molina, E. Rodríguez Braun

Publikováno v: Actas Urológicas Españolas v.30 n.10 2006
SciELO España. Revistas Científicas Españolas de Ciencias de la Salud
instname

Describimos un caso de flegmasia cerulea dolens secundaria a una trombosis venosa profunda por compresión de la vena cava inferior, en un varón de 31 años con un tumor germinal. Necesitó un tratamiento urgente con agentes fibrinolíticos, heparin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ca542ed284aeeff4f2ca9ca8279740a
https://doi.org/10.1016/s0210-4806(06)73583-5

Zobrazit plný text záznamu

A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors

Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research. 17(19)

Purpose: Insulin-like growth factor-1 receptor (IGF-1R) mediates cellular processes in cancer and has been proposed as a therapeutic target. Dalotuzumab (MK-0646) is a humanized IgG1 monoclonal antibody that binds to IGF-1R preventing receptor activa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eedfa16cc1c653411c494b3a76018d3
https://pubmed.ncbi.nlm.nih.gov/21810918

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání